Wed, Aug 14, 8:13 PM (153 days ago)
On August 13, 2024, Salarius Pharmaceuticals, Inc. filed a Form 8-K with the SEC, reporting a prospectus supplement for the registered offering of up to $335,921 in common stock. This offering is conducted under an At the Market Offering Agreement with Ladenburg Thalmann & Co. Inc., established on February 5, 2021. The prospectus supplement is linked to the company's prior registration statement filed on August 5, 2022, which was declared effective on August 16, 2022. Additionally, the filing includes a legal opinion from Hogan Lovells US LLP regarding the validity of the shares being registered. This move may impact the company's financial position by increasing liquidity through capital raised from the stock offering. The company continues to be classified as an emerging growth company, indicating potential for growth and investment opportunities.